RespireRx   Report issue

For profit Phase 2 Phase 3
Founded: Irvine CA United States (1988)
Status: Left NME R&D (2005)

Organization Overview

First Clinical Trial
2002
NCT00235352
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

RespireRx | RespireRx Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (1)

ampakine (2 trials)

Drugs in Phase 2 Trials (2)

ampalex (2 trials)

cx-1739 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 2)

Autistic Disorder (Phase 2)

Cognitive Dysfunction (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Fragile X Syndrome (Phase 2)

Respiratory Insufficiency (Phase 2)

Schizophrenia (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3